Nationwide evaluation of mutation-tailored anti-EGFR therapy selection in patients with colorectal cancer in daily clinical practice
暂无分享,去创建一个
I. Nagtegaal | H. Gelderblom | G. Vink | E. Steeghs | Q. Voorham | M. Elferink | K. Grünberg | M. Ligtenberg
[1] J. Desai,et al. Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] J. Desai,et al. CodeBreak 100: Activity of AMG 510, a novel small molecule inhibitor of KRASG12C, in patients with advanced colorectal cancer. , 2020 .
[3] A. Norden,et al. Genomic Profiling for KRAS, NRAS, BRAF, Microsatellite Instability, and Mismatch Repair Deficiency Among Patients With Metastatic Colon Cancer , 2019, JCO precision oncology.
[4] J. Desai,et al. Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E–Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] Chi Lin,et al. KRAS Testing, Tumor Location, and Survival in Patients With Stage IV Colorectal Cancer: SEER 2010-2013. , 2017, Journal of the National Comprehensive Cancer Network : JNCCN.
[6] J Ricke,et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] P. Juneau,et al. KRAS testing of patients with metastatic colorectal cancer in a community-based oncology setting: a retrospective database analysis , 2015, Journal of experimental & clinical cancer research : CR.
[8] Y. Yatabe,et al. Japanese Society of Medical Oncology Clinical Guidelines: RAS (KRAS/NRAS) mutation testing in colorectal cancer patients11 , 2015, Cancer science.
[9] Jennifer S. Lin,et al. Cost-effectiveness analysis of screening for KRAS and BRAF mutations in metastatic colorectal cancer. , 2012, Journal of the National Cancer Institute.
[10] Gwen L. Alexander,et al. KRAS Testing and Epidermal Growth Factor Receptor Inhibitor Treatment for Colorectal Cancer in Community Settings , 2012, Cancer Epidemiology, Biomarkers & Prevention.
[11] N. Normanno,et al. Uptake of KRAS mutation testing in patients with metastatic colorectal cancer in Europe, Latin America and Asia , 2011, Targeted Oncology.
[12] Sabine Tejpar,et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. , 2010, The Lancet. Oncology.
[13] Linda Mol,et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. , 2009, The New England journal of medicine.
[14] I. Nagtegaal,et al. BRAF mutation in metastatic colorectal cancer. , 2009, The New England journal of medicine.
[15] M. Choti,et al. NCCN Clinical Practice Guidelines in Oncology: colon cancer. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.
[16] J. Meyerhardt,et al. Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer , 2009, British Journal of Cancer.
[17] F. Siannis,et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. , 2008, The Lancet. Oncology.
[18] C. Bokemeyer,et al. KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience , 2008 .
[19] M. Casparie,et al. Pathology Databanking and Biobanking in The Netherlands, a Central Role for PALGA, the Nationwide Histopathology and Cytopathology Data Network and Archive , 2007, Cellular oncology : the official journal of the International Society for Cellular Oncology.
[20] David J Spiegelhalter,et al. Funnel plots for comparing institutional performance , 2005, Statistics in medicine.
[21] E. Kuipers,et al. Colorectal cancer , 2015, Nature Reviews Disease Primers.
[22] Medical Advisory Secretariat. KRAS Testing for Anti-EGFR Therapy in Advanced Colorectal Cancer: An Evidence-Based and Economic Analysis. , 2010, Ontario health technology assessment series.